Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous pembrolizumab with hyaluronidase versus intravenous pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer
2022-501506-36-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve (AUC) of Pembrolizumab Measured After the First Dose and Trough Concentration (Ctrough) of Pembrolizumab Measured at Steady State. Planned start Apr 2023; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501506-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501506-36-00.